Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

4(50.0%)

Phase 1

2(25.0%)

Phase 3

1(12.5%)

Phase 4

1(12.5%)

8Total

Phase 2(4)

Phase 1(2)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05706870Phase 2Completed

Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis

Role: collaborator

NCT04330326Phase 2Completed

Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease

Role: collaborator

NCT04573153Phase 2Terminated

Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients

Role: collaborator

NCT05361369Phase 1Completed

Bioavailability Study of EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule

Role: collaborator

NCT06056947Phase 3Completed

Evaluation of Efficacy and Safety of Two New Formulations Compared to Gynomax® XL Ovule

Role: collaborator

NCT05428202Phase 1Completed

Phase I Study of GN-037 Cream for Psoriasis

Role: collaborator

NCT04828564Phase 2Unknown

Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19

Role: collaborator

NCT03839875Phase 4Completed

Evaluation of Efficacy and Safety of Gynomax® XL Ovule

Role: collaborator

All 8 trials loaded